Drugs / TQB3002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06662760 | Dec 2024 → Nov 2025 overdue | cancer of unknown primary site | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-04-27 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Results 科研实力获国际认可！正大天晴2款创新药临床前研究亮相2025 AACR cttq.com ↗
临床前研究[1]显示，TQB3002具有抑制EGFR单突变（如L858R）、双突变（如L858R/T790M）及三突变（如L858R/T790M/C797S）的潜力，对三代EGFR-TKI耐药的C797S突变效果更优。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-04-27 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 科研实力获国际认可！正大天晴2款创新药临床前研究亮相2025 AACR cttq.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB3002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06662760 ↗ |
| Action | Inhibit | “TQB3002 is a fourth-generation small molecule Epidermal growth factor receptor (EGFR) inhibitor, which inhibits relevant tyrosine kinase activity and intracellular...” NCT06662760 ↗ |
| Modality | Small molecule | “TQB3002 is a fourth-generation small molecule Epidermal growth factor receptor (EGFR) inhibitor” NCT06662760 ↗ |